Skip to main content
TWST logo

TWST · Twist Bioscience Corp

Track TWST — free
$116.35 +4.35 (+3.88%) At close · Nov 18
Market Cap
$7.93B
Shares
68.18M
Volume · Nov 18 2.23M Avg daily vol (3M) 2.48M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$116.35 Open$112.11 Day$109.97–119.81 52W close$25.45–205.00 Avg vol 30d2.5M Short int9.8M · 14.4% of shares · 4.4d Short vol55% Last earningsNov 12, 2026 DataJan 2020–Nov 2026 Filing10-K · Nov 16

Up next

Feb 1, 2027 Est · unconfirmed · in 11 wks

Latest documents

2026
Nov 16
Annual report 10-K FY2026, ended Sep 30
Revenue up 22% to $459.4 million as net loss widens

Twist Bioscience reported revenue up 22% to $459.4 million for fiscal 2026 from $376.6 million, while net loss widened to $130.2 million from $77.7 million.

Revenue $459.43M ▲ 22.0% Net loss $130.2M Diluted EPS -$2.08
Read from the MD&A section
2 source passages
Revenue increased 22% to $459.4 million for the year ended September 30, 2026, as compared to $376.6 million for the year ended September 30, 2025. We generated revenue of $459.4 million, $376.6 million, and $313.0 million in the years ended September 30, 2026, September 30, 2025, and September 30, 2024, respectively, while incurring net losses of $130.2 million, $77.7 million and $208.7 million in the years ended September 30, 2026, 2025 and 2024, respectively. Open the document at this passage
Nov 12
Earnings call
Fiscal 2027 revenue guidance: $550 million to $560 million

Twist Bioscience expects fiscal 2027 revenue of $550 million to $560 million, approximately 21% growth at the midpoint, including $100 million of AI drug discovery revenue. Fiscal 2026 revenue was $459.4 million, up 22%.

3 source passages
Welcome to the TWIST Bioscience Fiscal 2026 Fourth Quarter Financial Results Conference Call. For fiscal 2027, we expect. Total revenue of $550 million to $560 million, representing growth of approximately 21% at the midpoint. Our initial full-year revenue guidance assumes $100 million in AI drug discovery revenue. For the full year, revenue was $459.4 million, compared with $376.6 million in Fiscal 25, growth of 22%. Open the document at this passage
Nov 12
Current report 8-K
Fiscal 2026 revenue reached $459.4 million; 2027 guidance $550 million to $560 million

Twist Bioscience reported fiscal 2026 revenue of $459.4 million, an increase of 22%, and fourth-quarter revenue of $126.6 million, an increase of 28%. Fiscal 2027 revenue guidance is $550 million to $560 million, including first-quarter guidance of $130 million to $132 million.

Financial results
6 source passages
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today reported financial results and business highlights for the fourth quarter and full year fiscal 2026 ended September 30, 2026. — Record revenue of $459.4 million in Fiscal 2026; Increase of 22% over $376.6 million in Fiscal 2025 — — Record revenue of $126.6 million in 4QFY26; Increase of approximately 28% over $99.0 million in 4QFY25; 15th consecutive quarter of sequential growth — — Fiscal 2027 revenue guidance of $550M-$560M, growth of 21% year over year at the midpoint — •Total revenue in the range of approximately $550 million to $560 million, growth of approximately 21% year over year at the midpoint. •Total revenue of approximately $130 million to $132 million, growth of approximately 26% year over year at the midpoint and continued sequential growth Open the document at this passage
Aug 19
Current report 8-K
Other events AI summary on its way
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$459.43M
Trailing 12 months
Net income (TTM)
−$130.20M
Trailing 12 months
Revenue growth YoY
+27.9%
Year over year
Operating margin
-30.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.0%
Year over year · more shares
Price change (1Y)
+323.3%
Trailing year
Short interest
14.4%
Latest settlement · 4.4 days to cover
View all 125 metrics

AI Brief

Q4 FY26 earnings call · Nov 12, 2026
Q4 FY26

TL;DR. Twist delivered 22% fiscal 2026 revenue growth, 175% AI drug-discovery growth, gross-margin expansion and a 15th consecutive quarter of sequential growth, and guides to $550-$560 million of fiscal 2027 revenue with positive adjusted EBITDA. Risks include the fiscal 2026 net loss of $130.2 million, continued full-year adjusted-EBITDA losses, deployment-related margin pressure, uncertain AI demand, competitive obsolescence risk and supplier concentration.

Bullish
  • + AI drug discovery revenue grew 175% to $59.1 million and orders more than doubled in fiscal 2026 new
  • + Fiscal 2026 revenue increased 22% to $459.4 million new
  • + Fourth-quarter revenue grew 28% to $126.6 million, marking a 15th consecutive quarter of sequential growth new
  • + Fiscal 2026 gross margin improved to 52.4% from 50.7% new
  • + Fiscal 2027 revenue guidance is $550 million to $560 million, representing approximately 21% growth at the midpoint new
  • + Management expects adjusted EBITDA to be positive for fiscal 2027 new
Bearish
  • − Fiscal 2026 net loss widened to $130.2 million from $77.7 million new
  • − Fiscal 2026 adjusted EBITDA remained negative at $35.9 million new
  • − Fiscal 2027 capacity investments are expected to create a two-to-three-point gross-margin headwind new
  • − Demand for AI-enabled drug discovery may not continue at current rates new
  • − Rapid technology changes and competition could render Twist's products obsolete or noncompetitive new
  • − Twist depends on one supplier for a critical component new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +23%
above
Price vs 50-day avg −22%
below
RSI (14) 42
neutral
MACD trend Negative
52-week position 51%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −22%
trailing
6-month return +74%
trailing
YTD return +267%
this year
Relative strength +77%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $149 › 200d $94 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +139 funds added
Insider flow Distributing
Net -$15.5M over 90 days · 100% sells
Short interest Falling
14.43% of shares out · ▼ -3.6% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
441 holders — near 3-yr high, broad support
Squeeze score 68
elevated · 0–100
Fundamentals
Weak
Revenue growth +22%
Y/Y
EPS growth −60%
Y/Y
Free cash flow $-89.0M
Quant / Vol
risk profile
Very High
Volatility 84%
annualized · 1-yr
Max drawdown −49%
past year
ATR 13.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 8 of last 8
Latest guidance · from the Earnings Call filed Nov 12, 2026
Over fiscal 2027 and fiscal 2028
Capital expenditures $150M
Landlord-funded tenant improvements at least $30M
fiscal 2027
Total revenue $550M – $560M
prior FY $459.43M midpoint +20.8% Y/Y
AI drug discovery revenue $100M
Capital expenditures $75M
Gross margin 52.5% – 53%
first quarter of fiscal 2027
Revenue $130M – $132M
prior qtr $118.38M midpoint +10.7% QoQ
DNA synthesis and protein solutions at least 25%
NGS applications at least 25%
2027
CapEx $75M
Depreciation $15M
in the future
Gross margin 60%
Drop through 75% – 80%
Prior guidance period ended · from the Earnings Call filed Aug 3, 2026
Total revenue · fiscal 2026 $456M – $457M
Total revenue · Q4 of fiscal 2026 $123M – $124M
Guided vs delivered · last 8 settled
Total revenue fiscal 2026
guided $456M – $457M
$459.43M Beat +0.6%
Total revenue Q4 of fiscal 2026
guided $123M – $124M
$126.64M Beat +2.5%
Total revenue Q3 of fiscal 2026
guided $114M – $115M
$118.38M Beat +3.4%
Total revenue second quarter (fiscal 2026)
guided $107M – $108M
$110.72M Beat +3.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+23% Bullish
Price vs 50-day avg
−22% Bearish
RSI (14)
42 Neutral
MACD trend
Negative Bearish
52-week position
51% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $149 › 200d $94 — 50d above 200d
Institutional flow Accumulating
+29% holders QoQ · +139 funds added
Insider flow Distributing
Net -$15.5M over 90 days · 100% sells
Short interest Falling
14.43% of shares out · ▼ -3.6% MoM · 4.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
441 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $25 Now $116 · 51% Range high $205
vs 200-day avg +23% vs 50-day avg -22%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
2018 ESPP expense $2.1M year ended September 30, 2026 filing —
Customers served 4,100 fiscal year 2026 filing —
Employer matching contributions expense $3.5M year ended September 30, 2026 filing —
Genes shipped 1.34M Year ended September 30, 2026 filing —
revenue recognized over time $58.7M fiscal 2026 filing —
revenue recognized over time as a share of total revenue 13% fiscal 2026 filing —
Weighted-average remaining lease term (in years) - operating leases 13.92 Year ended September 30, 2026 filing —
Adjusted EBITDA non-GAAP -$11.3M the third quarter of fiscal 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP net (loss) income -35.05M
-1.5M Interest income
+311K Income tax expense
+6.78M Depreciation and amortization
+0K Litigation settlement costs, net of recoveries
+0K Gain on sale of business
-40K Other (income) expense, net
+18.18M Stock-based compensation expense
= Adjusted EBITDA -11.33M
Gross margin 52.8% the third quarter of fiscal 2026 —
Number of customers who purchased products 2,664 the three months ended June 30, 2026 filing —
Number of genes shipped 369K the three months ended June 30, 2026 filing —
Physically shipped genes 369,000 the third quarter of fiscal 2026 —
Shipped products to customers 2,650 the third quarter of fiscal 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TWST
Twist Bioscience Corp
this stock
$7.93B +266.8% +22.0% — 14.4%
VRTX
Vertex Pharmaceuticals Inc
$136.01B +18.3% +46.2% 34.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$97.81B +22.5% +20.8% 20.9 2.1%
MRNA
Moderna, Inc.
$79.63B +567.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
441
% held
113.9%
Net QoQ
+1.3M sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
404
View
Short & Settlement
Short Interest Falling
Shares short
9.8M
Days to cover
4.4d
Change
-371.7K sh
View
Short Volume
Short vol %
55%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
314
Value
$50.2K
As of
Oct 28, 2026
View
Off-Exchange
Off-exchange %
48.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$15.5M
Buyers / Sellers
0 / 6
Buyers Sellers
View
Congressional Trades Sell
Member
Dwight Evans
Amount
$1.0K–$15.0K
Traded
Mar 30, 2022
View
Financials
Financials
Net income (FY)
$-130.2M
EPS diluted
$-2.08
View
Filings
SEC Filings
Latest
10-K
Filed
Nov 16, 2026
This year
23

Twist Bioscience reported revenue up 22% to $459.4 million for fiscal 2026 from $376.6 million, while net loss widened to $130.2 million from $77.7 million.

View
Proposed Sales
Value
$169.7K
Shares
1.6K
Filed
Nov 16, 2026
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 1, 2026
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
Twist Bioscience Announces Fiscal…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
TWST -5.1% -22.0% +74.0% -23.8% +266.8%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -1.2% -16.4% +77.5% -20.5% +259.7%
Key facts CIK 1581280 CUSIP 90184D100 13F (30d) 454 filings 419 filers Visit website Investor relations